Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.

Journal of clinical pharmacology - 1 Jan 2013

Kakuda Thomas N, Van Solingen-Ristea Rodica, Aharchi Fatima, Smedt Goedele De, Witek James, Nijs Steven, Vyncke Veerle, Hoetelmans Richard M W

Abstract excerpt

The nonnucleoside reverse transcriptase inhibitor etravirine, approved for use in treatment-experienced, HIV-1-infected patients, is a substrate and inducer of cytochrome P450 (CYP) 3A4 and a substrate and inhibitor of CYP2C9/CYP2C19. Pharmacokinetic interactions and safety of etravirine 200 mg twice daily coadministered with fluconazole 200 mg daily or voriconazole 200 mg twice daily, both inhibitors of CYP3A4,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross-Over Studies
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Fluconazole

Share to Nitriles

Share to Pyridazines

Share to Triazoles

Share to Voriconazole

Source

Identifiers

PMID: 23400742
DOI: 10.1177/0091270011433329

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.PMID 23400742Read ↗

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy SubjectsSemantic proximity Read ↗

CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.Semantic proximity Read ↗

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patientsSemantic proximity Read ↗

Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.Semantic proximity Read ↗

Pharmacokinetic drug-drug interaction study between raltegravir and citalopram.Semantic proximity Read ↗

Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.Semantic proximity Read ↗

Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism.Semantic proximity Read ↗

Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers.Semantic proximity Read ↗

Efavirenz.Semantic proximity Read ↗

Clinical uses of non-nucleoside reverse transcriptase inhibitorsSemantic proximity Read ↗

Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?Semantic proximity Read ↗

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.